Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
Associated filings
- 28 Mar 23 424B5 Prospectus supplement for primary offering
- 27 Oct 22 424B5 Prospectus supplement for primary offering
- 25 Oct 22 424B5 Prospectus supplement for primary offering
- 31 Mar 22 424B5 Prospectus supplement for primary offering
- 15 Oct 21 EFFECT Notice of effectiveness
-
5 Oct 21 S-3 Shelf registration
TSHA similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in this Registration Statement on Form S-3 of our report dated March 3, 2021, relating to the financial statements of Taysha Gene Therapies, Inc. (“the Company”) appearing in the Annual Report on Form 10-K of Taysha Gene Therapies, Inc. for the year ended December 31, 2020, and to the reference to us under the heading “Experts” in the Prospectus, which is part of this Registration Statement.
/s/ Deloitte & Touche LLP
Dallas, Texas
October 5, 2021